← All trials
NCT04382066
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- May 11, 2020
- Last posted
- May 15, 2020
- Enrollment
- 27
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PharmaMarLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- Hospital Universitario Ramon y CajalOverall official - principal investigator
- Apices Soluciones S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.